Action IMUX IMMUNIC, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Immunic, Inc.

Actions

IMUX

US4525EP1011

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 28/06/2024 		Varia. 5j. Varia. 1 janv.
1,11 USD +8,82% Graphique intraday de Immunic, Inc. 0,00% -26,00%
08/05 Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024
08/05 Immunic, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day
AQ
Immunic to Participate in Industry and Scientific Conferences in June
PR
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
AQ
Immunic chief medical officer discusses promising treatments to mark World IBD Day
AQ
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
AQ
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
AQ
Immunic : Q1 2024 News Release
PU
Immunic: Q1 Earnings Snapshot
AQ
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR
Immunic to Participate in Investor and Scientific Conferences in May
PR
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
AQ
Immunic Announces Publication of Extended Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology and Neuroinflammation
AQ
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
PR
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
AQ
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
PR
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
AQ
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
AQ
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
PR
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
AQ
Immunic to Participate in Investor and Scientific Conferences in March
PR
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action IMUX
  4. Actualités Immunic, Inc.
  5. Communiqués